comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 20:32:06 - browse：32263

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

STAT wants to know your pick for a great summer read or listen

Eliminate the waiting period for sterilization covered by Medicaid

Canadians with cystic fibrosis outlive Americans by a decade

Dexcom's push to bring CGM to type 2 diabetes patients

What affirmative action's end means to a medical student

Washington mulls new rules to avert another Change Healthcare

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Medical records are filled with copy

Vertex Pharmaceuticals may move headquarters in Boston

Moonlake's readout produced a cash windfall. Risks remain

Lupron, used to halt puberty in children, may cause lasting health problems

Duchenne breakthrough therapy leaves behind pioneering families

Primary care physicians play key roles in Alzheimer's management

Novavax promises a turnaround & Lilly roils the obesity market

Lupron, used to halt puberty in children, may cause lasting health problems

hotspot

Canadians with cystic fibrosis outlive Americans by a decade

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

States should stop sabotaging methadone treatment reform

Vertex Pharmaceuticals may move headquarters in Boston

AstraZeneca lung cancer study comes in below expectations

Why the world’s most expensive drug might be worth the price

Wikipedia

Wikipedia

focus

focus